Novo Nordisk A/S (NVO) rose 0.7% in late trading on Wednesday. The company reported mixed third-quarter results and revised its growth expectations downward. Reports indicate that Novo Nordisk has increased its offer for Metsera to up to $10 billion, surpassing Pfizer's $8.1 billion bid. During ongoing antitrust and merger litigation, a judge rejected Pfizer's attempt to block Novo Nordisk's acquisition efforts.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.